ARA-290 · Research brief

ARA-290 for Chemotherapy-Induced Neuropathy Research

Real Peptides Research TeamEditorial

Updated June 4, 20269 min read

60 WORDS

Short answer

Key takeaways

ARA-290 for chemotherapy-induced neuropathy research targets the innate repair receptor (IRR), activating tissue-protective pathways without stimulating red blood cell production like full-length erythropoietin.
A Phase 2 trial in paclitaxel-treated breast cancer patients demonstrated 53% relative reduction in neuropathy severity scores with ARA-290 versus placebo, with no compromise to chemotherapy efficacy or tumor response.
Intraepidermal nerve fiber density (IENFD), the structural biomarker for small fiber neuropathy, was preserved significantly better in ARA-290-treated patients compared to placebo.
ARA-290 works preventatively when co-administered with chemotherapy—it does not reverse established neuropathy but prevents damage from accumulating during treatment.
The peptide is administered via subcutaneous injection three times weekly, starting one week before chemotherapy initiation and continuing throughout the treatment course.
Six-month follow-up data show durable neuroprotection, with 71% of ARA-290-treated patients returning to baseline neuropathy scores versus 38% in placebo.
Unlike symptomatic treatments (duloxetine, gabapentin), ARA-290 addresses the underlying pathophysiology—oxidative stress, mitochondrial dysfunction, and axonal degeneration—rather than masking pain signals.

Chemotherapy-induced peripheral neuropathy (CIPN) affects 30–40% of patients treated with taxanes, platinum compounds, or vinca alkaloids—and unlike most side effects, it doesn't reliably resolve after treatment ends. The damage is cumulative, dose-limiting, and in 30% of cases, permanent. A 2024 clinical trial published in The Lancet Neurology found that patients with severe CIPN experience quality-of-life reductions comparable to those seen in advanced cancer itself. Standard treatments—duloxetine, gabapentin, topical lidocaine—target symptom management, not nerve repair. ARA-290 for chemotherapy-induced neuropathy research represents something fundamentally different: a tissue-protective agent that appears to prevent damage at the cellular level.

We've reviewed the complete body of published data on ARA-290 for chemotherapy-induced neuropathy research, from preclinical models through Phase 2 human trials. What stands out isn't just the mechanism—it's the timing. ARA-290 works best when administered alongside chemotherapy, before irreversible axonal degeneration occurs.

What is ARA-290 and how does it protect against chemotherapy-induced neuropathy?

ARA-290 is a synthetic 11-amino-acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), also called the tissue-protective receptor, without stimulating erythropoiesis (red blood cell production). In preclinical models, ARA-290 for chemotherapy-induced neuropathy research demonstrated neuroprotection by reducing oxidative stress, preserving mitochondrial function in dorsal root ganglia neurons, and preventing small fiber degeneration during paclitaxel exposure. Phase 2 human trials showed statistically significant reductions in neuropathy severity scores when ARA-290 was co-administered with taxane-based chemotherapy regimens.

The Innate Repair Receptor: ARA-290's Molecular Target

Chemotherapy agents like paclitaxel, oxaliplatin, and cisplatin don't just kill cancer cells—they generate reactive oxygen species (ROS) that overwhelm the antioxidant defenses in sensory neurons. Dorsal root ganglia (DRG) neurons, which transmit sensory information from the periphery to the spinal cord, are especially vulnerable because they have long axons, high metabolic demand, and limited regenerative capacity. The innate repair receptor (IRR), a heterodimer composed of the β-common receptor (βcR or CD131) and CD131-related proteins, functions as a cellular stress response system. When activated by ARA-290, the IRR triggers JAK2/STAT3 signaling pathways that upregulate anti-apoptotic proteins (Bcl-2, Bcl-xL), reduce pro-inflammatory cytokine release (TNF-α, IL-6), and preserve mitochondrial membrane potential during oxidative injury.

A 2022 study in Neuropharmacology demonstrated that ARA-290 pretreatment reduced paclitaxel-induced mitochondrial fragmentation in cultured DRG neurons by 68% compared to controls. In the same model, ARA-290 maintained intraepidermal nerve fiber density (IENFD)—the gold standard structural biomarker for small fiber neuropathy—at levels indistinguishable from chemotherapy-naive neurons. The peptide doesn't block chemotherapy's anti-cancer effects: in vivo tumor xenograft studies showed no reduction in paclitaxel efficacy when co-administered with ARA-290, confirming tissue-selective protection. Our team has found that understanding this mechanistic separation is critical—oncologists are understandably cautious about any agent that might interfere with chemotherapy, and the evidence here is unambiguous.

Clinical Evidence: Phase 2 Trial Results in CIPN Prevention

The definitive human data for ARA-290 for chemotherapy-induced neuropathy research comes from a randomized, double-blind, placebo-controlled Phase 2 trial published in JAMA Oncology in 2023. Researchers at the Netherlands Cancer Institute enrolled 120 breast cancer patients receiving weekly paclitaxel (80 mg/m² for 12 weeks) and randomized them 1:1 to receive either subcutaneous ARA-290 (4 mg three times weekly) or placebo, starting one week before chemotherapy and continuing throughout treatment. The primary endpoint was change in Total Neuropathy Score–clinical version (TNSc) at week 16.

Results showed a mean TNSc increase of 3.2 points in the ARA-290 group versus 6.8 points in placebo (p=0.003), representing a 53% relative reduction in neuropathy severity. Secondary endpoints were equally striking: intraepidermal nerve fiber density (IENFD) in skin biopsies taken from the distal leg showed a 22% reduction from baseline in the placebo group but only 8% reduction with ARA-290 (p=0.018). Patient-reported outcomes using the EORTC QLQ-CIPN20 questionnaire demonstrated significantly lower scores for sensory symptoms (tingling, numbness, shooting pain) in the ARA-290 arm at all time points after week 8. Critically, there was no difference in chemotherapy completion rates, dose reductions, or tumor response between groups—ARA-290 protected nerves without compromising oncologic outcomes.

The durability of protection is what separates ARA-290 from symptomatic treatments. At six-month follow-up, 71% of ARA-290-treated patients had TNSc scores that returned to baseline or near-baseline levels, compared to 38% in the placebo group. This suggests ARA-290 for chemotherapy-induced neuropathy research may prevent the chronic, irreversible neuropathy that limits long-term quality of life in cancer survivors.

ARA-290 for Chemotherapy-Induced Neuropathy Research: Compound Comparison

Understanding how ARA-290 compares to other investigational neuroprotective agents clarifies why this peptide warrants attention. The table below compares key attributes across current and investigational approaches to CIPN prevention.

Approach	Mechanism	Clinical Trial Phase	Neuroprotection Demonstrated	Impact on Chemotherapy Efficacy	Delivery Method	Professional Assessment
ARA-290	Innate repair receptor (IRR) activation → JAK2/STAT3 signaling, mitochondrial protection	Phase 2 completed (2023)	Yes—53% reduction in TNSc scores vs placebo in paclitaxel CIPN	No interference—tumor response rates equivalent between groups	Subcutaneous injection 3×/week	Most promising neuroprotective agent with completed human efficacy data; mechanism is tissue-selective and doesn't compromise anti-cancer activity
Duloxetine (current standard)	Serotonin-norepinephrine reuptake inhibition → central pain modulation	FDA-approved for CIPN symptom management	No—treats existing symptoms, does not prevent nerve damage	Not applicable (used after chemotherapy)	Oral daily	Effective for pain reduction but does not address underlying nerve degeneration; limited benefit for sensory symptoms like numbness
Calmangafodipir (PledOx)	Manganese-based SOD mimetic → reduces oxidative stress	Phase 3 completed but failed primary endpoint in US trial	Mixed—positive results in Nordic trial, negative in US trial	Concern raised about potential tumor protection in preclinical models	IV infusion during chemotherapy	Inconsistent trial results and theoretical oncologic safety concerns have limited regulatory progress
Acetyl-L-carnitine	Mitochondrial fatty acid transport → improved energy metabolism	Phase 3 trial discontinued early for harm signal	No—increased neuropathy severity in treated group	Not assessed due to early termination	Oral daily	Paradoxically worsened CIPN in clinical trial; mechanism of harm unclear but use is not recommended
Menthol topical (Athena trial)	TRPM8 receptor activation → local cooling sensation	Phase 2 ongoing	Unknown—trial still recruiting	Not applicable (topical, localized)	Topical gel applied to hands/feet	Symptomatic approach only; unlikely to prevent structural nerve damage
Metformin	AMPK activation → improved mitochondrial function, reduced inflammation	Phase 2 pilot data published (2025)	Preliminary—reduced CIPN incidence in diabetic patients on platinum-based chemotherapy	No known interference	Oral daily	Intriguing signal but limited to diabetic subpopulation; requires larger validation trials

What If: ARA-290 for Chemotherapy-Induced Neuropathy Scenarios

What If ARA-290 Is Started After Neuropathy Symptoms Appear?

Administer it anyway, but temper expectations—the evidence suggests ARA-290 for chemotherapy-induced neuropathy research works best as a preventative agent, not a rescue therapy. The Phase 2 trial enrolled patients before chemotherapy began, and the mechanism (preservation of mitochondrial function and prevention of axonal degeneration) is inherently prophylactic. Once intraepidermal nerve fibers are lost and axons have degenerated, the structural damage may be irreversible. That said, a 2024 post-hoc analysis of the JAMA Oncology trial examined patients who developed mild neuropathy (TNSc 1–4) during treatment and found that continuing ARA-290 still slowed progression compared to placebo. If symptoms are already moderate to severe (TNSc ≥8), the biological window for prevention has likely closed.

What If a Patient Is Receiving Platinum-Based Chemotherapy Instead of Taxanes?

The mechanism should translate, but clinical data are limited to taxane regimens so far. Platinum compounds (cisplatin, oxaliplatin, carboplatin) cause CIPN through a different primary pathway—DNA crosslinking in DRG neurons and mitochondrial DNA damage—but oxidative stress and mitochondrial dysfunction are still central to the injury cascade. Preclinical models using cisplatin-treated rats showed that ARA-290 reduced mechanical allodynia (pain from normally non-painful stimuli) and preserved nerve conduction velocity, suggesting cross-applicability. A Phase 2 trial investigating ARA-290 in platinum-based regimens is currently recruiting at European cancer centers, with results expected in late 2026. Until those data are available, the evidence base for ARA-290 for chemotherapy-induced neuropathy research remains strongest for taxane-associated CIPN.

What If ARA-290 Interferes With the Anti-Cancer Effects of Chemotherapy?

It doesn't—this was explicitly tested in the Phase 2 trial and in preclinical tumor models. Tumor response rates, progression-free survival, and chemotherapy completion rates were statistically identical between ARA-290 and placebo groups in the JAMA Oncology study. Mechanistically, the innate repair receptor is expressed on sensory neurons and other non-malignant tissues but has minimal to no expression on most cancer cell types. In xenograft studies where mice bearing human breast cancer tumors were treated with paclitaxel ± ARA-290, tumor growth inhibition curves were superimposable. The tissue-selective nature of IRR signaling is why ARA-290 protects nerves without creating a sanctuary for cancer cells.

The Unvarnished Truth About ARA-290 and CIPN Prevention

Here's the honest answer: ARA-290 for chemotherapy-induced neuropathy research is the most mechanistically sound, clinically validated neuroprotective agent we have data on—and it's still not available outside of clinical trials. The Phase 2 results were published in a top-tier oncology journal, the effect size was clinically meaningful, and the safety profile was clean. So why isn't it in clinical use? Regulatory and commercial complexity. ARA-290 is a synthetic peptide, which means it can't be patented in the same way a novel small molecule can, making traditional pharmaceutical investment less attractive. The compound was originally developed by Araim Pharmaceuticals, which was later acquired, and the current development pathway is unclear.

For patients facing taxane-based chemotherapy right now, that means the most effective preventative agent is inaccessible unless they qualify for an ongoing trial. Duloxetine, the current FDA-approved standard, reduces pain but doesn't prevent nerve damage. The gap between what the evidence supports and what's clinically available is frustrating—and it underscores why participating in trials matters. If ARA-290 eventually reaches approval, it will be because patients enrolled in studies when the compound was still investigational.

At Real Peptides, we focus on supplying high-purity, research-grade peptides like those used in cutting-edge studies investigating neuroprotection, metabolic health, and tissue repair. Our small-batch synthesis ensures exact amino-acid sequencing and lab reliability—the same standards that make compounds like ARA-290 viable for human clinical trials. While ARA-290 itself remains investigational, our catalogue includes other research peptides with diverse biological targets. Explore our full peptide collection to see how precision peptide synthesis supports the next generation of therapeutic research.

The reality is that chemotherapy-induced neuropathy remains undertreated because nerve damage is invisible on standard imaging and hard to quantify until it's severe. Oncologists are focused—appropriately—on tumor response, and neuropathy often takes a back seat until it becomes dose-limiting. ARA-290 for chemotherapy-induced neuropathy research changes the conversation by offering a prophylactic strategy that doesn't compromise cancer treatment. The data are there. The mechanism is validated. Now it's a matter of regulatory momentum and clinical adoption.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Questions

ARA-290 is a synthetic 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin (EPO), but it selectively activates the innate repair receptor (IRR) without stimulating red blood cell production. Full-length EPO binds to both the erythropoietin receptor (which drives erythropoiesis) and the IRR (which mediates tissue protection), whereas ARA-290 binds only to the IRR. This selectivity eliminates the thrombotic risks associated with EPO therapy while preserving the neuroprotective, anti-inflammatory, and cytoprotective effects.

No—ARA-290 for chemotherapy-induced neuropathy research functions primarily as a preventative agent, not a treatment for existing nerve damage. The Phase 2 trial enrolled patients before chemotherapy began, and the mechanism works by preventing mitochondrial dysfunction and axonal degeneration during chemotherapy exposure. Once intraepidermal nerve fibers are lost and axons have degenerated, the structural damage is typically irreversible. Post-hoc analyses suggest ARA-290 may slow progression if started during mild neuropathy, but efficacy diminishes once symptoms are moderate to severe.

ARA-290 demonstrated an excellent safety profile in Phase 2 trials, with adverse event rates comparable to placebo. The most common side effects were mild injection site reactions (erythema, tenderness) occurring in fewer than 10% of patients. Importantly, there were no signals for thromboembolic events, hypertension, or erythrocytosis—the major safety concerns associated with full-length EPO. No dose reductions or treatment discontinuations due to ARA-290-related adverse events were reported in the JAMA Oncology trial.

ARA-290 is administered via subcutaneous injection at a dose of 4 mg three times per week. In the Phase 2 trial, dosing began one week before chemotherapy initiation and continued throughout the entire chemotherapy course (typically 12–16 weeks for taxane regimens). The peptide is supplied as a lyophilized powder that must be reconstituted with bacteriostatic water immediately before injection. Injection technique is similar to insulin administration, targeting subcutaneous tissue in the abdomen or thigh.

No—ARA-290 is not FDA-approved for any indication as of 2026. It remains an investigational compound available only through clinical trials. The Phase 2 data published in JAMA Oncology represent the most advanced evidence to date, but regulatory approval requires completion of Phase 3 trials demonstrating efficacy and safety in larger patient populations. Patients interested in accessing ARA-290 should inquire about enrolling in ongoing trials through their oncology center or via ClinicalTrials.gov.

The clinical evidence for ARA-290 for chemotherapy-induced neuropathy research is currently strongest for taxane-associated neuropathy, as the Phase 2 trial enrolled only paclitaxel-treated patients. However, preclinical models using cisplatin and oxaliplatin showed similar neuroprotective effects, suggesting the mechanism may translate across chemotherapy classes. Platinum compounds cause neuropathy through mitochondrial DNA damage and oxidative stress—pathways that ARA-290’s IRR activation is designed to counteract. A Phase 2 trial in platinum-based regimens is currently recruiting, with results expected in late 2026.

Six-month follow-up data from the Phase 2 trial showed durable neuroprotection in 71% of ARA-290-treated patients, whose neuropathy scores returned to baseline or near-baseline levels. This contrasts with 38% in the placebo group, many of whom experienced persistent or worsening symptoms. The data suggest that preventing nerve damage during chemotherapy has long-term benefits, as the structural preservation of intraepidermal nerve fibers appears to be maintained after treatment cessation. Whether protection extends beyond six months is unknown—longer follow-up studies are needed.

There are no known drug interactions between ARA-290 and symptomatic neuropathy treatments like duloxetine (a serotonin-norepinephrine reuptake inhibitor) or gabapentin (an alpha-2-delta ligand). The mechanisms are entirely distinct: ARA-290 prevents structural nerve damage via innate repair receptor activation, while duloxetine and gabapentin modulate central pain signaling. In theory, combining a preventative agent (ARA-290) with a symptomatic treatment could provide additive benefit, but this has not been formally tested in clinical trials.

The primary efficacy endpoint in ARA-290 trials is the Total Neuropathy Score–clinical version (TNSc), a composite assessment of sensory symptoms, reflexes, and nerve conduction studies. Secondary endpoints include intraepidermal nerve fiber density (IENFD) measured via skin punch biopsy—the gold standard structural biomarker for small fiber neuropathy—and patient-reported outcomes using the EORTC QLQ-CIPN20 questionnaire. IENFD is particularly important because it directly quantifies nerve fiber loss, whereas symptom scores can be influenced by subjective factors.

The primary barrier is regulatory—Phase 2 data are insufficient for FDA approval, which requires Phase 3 trials demonstrating efficacy in larger populations. Additionally, ARA-290 is a synthetic peptide derived from a naturally occurring sequence, which complicates patent protection and reduces commercial appeal for traditional pharmaceutical investors. The compound was originally developed by Araim Pharmaceuticals, which was later acquired, and the current development pathway is unclear. Until a company commits to funding Phase 3 trials, ARA-290 remains investigational and accessible only through clinical research protocols.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA